Related Experiment Video
Updated: Jun 15, 2026

Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
Published on: April 2, 2021
Ocular findings of oral sildenafil use in term and near-term neonates
Rinat Kehat1, Dean J Bonsall, Robert North
1Israel Institute of Technology, Haifa, Israel.
Insights
Sildenafil use in neonates did not show increased ocular complications. Routine ophthalmologic exams are not necessary for term and near-term infants receiving this medication.
Area of Science:
- Neonatal Medicine
- Ophthalmology
- Pharmacology
Background:
- Sildenafil, a phosphodiesterase type 5 inhibitor, is used for persistent pulmonary hypertension in neonates.
- Concerns exist regarding potential ocular complications, including exacerbation of retinopathy of prematurity (ROP).
- The risk of ocular issues in neonates not otherwise at risk for ROP is unknown.
Purpose of the Study:
- To assess the risk of ocular complications in term and near-term neonates receiving sildenafil.
- To determine if routine ophthalmologic examinations are warranted for these infants.
Main Methods:
- A pediatric ophthalmologist evaluated 22 neonates who received oral sildenafil for over two weeks.
- Infants had a birth gestational age >34 weeks and birth weight >2,100 g.
Main Results:
- Four patients exhibited ocular findings: bacterial conjunctivitis (2), optic nerve hypoplasia with coloboma and nystagmus (1), and optic disk atrophy with nystagmus following a hypotensive episode (1).
- These findings were deemed unrelated to sildenafil and improved despite continued drug use.
Conclusions:
- The study's findings do not support the necessity of routine ophthalmologic examinations for term and near-term neonates treated with sildenafil.
- Sildenafil use in this population does not appear to necessitate specialized eye screening.
Background:
Sildenafil is a phosphodiesterase type 5 inhibitor used as a therapeutic adjunct in critically ill neonates with persistent pulmonary hypertension. Sildenafil is associated with several ocular complications in adults and is suspected to exacerbate retinopathy of prematurity (ROP). The risk of ocular complication in sildenafil-treated newborns, not otherwise at risk for the development of ROP, is unknown.
Methods:
Twenty-two neonates with birth gestational age greater than 34 weeks and birth weight over 2,100 g who received oral sildenafil for more than 2 weeks were assessed by a pediatric ophthalmologist for potential ocular complications.
Results:
Four patients had ocular findings: 2 had bacterial conjunctivitis; 1 had optic nerve hypoplasia, choroidal coloboma, and nystagmus; 1 had previously suffered from a hypotensive episode and had a documented cortical injury accompanied by bilateral optic disk atrophy and nystagmus. All cases seemed unrelated to sildenafil use and improved despite continued use of the drug.
Conclusions:
Our results do not support the need for a routine ophthalmologic examination in term and near-term neonates receiving sildenafil.
Related Concept Videos
Teratogenicity
Glaucoma: Overview
Drug Dosing: Infants and Children
Development of the Oral Microbiota
Angle Closure Glaucoma: Treatment

